Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 severe or critically meta-analysis

Lescure (Sarilumab 200mg), 2021
RCTsarilumab low dose (200mg)placeboCOVID-19 severe or criticallysome concern
161/86 inconclusive 21% 3%
Lescure (Sarilumab 400mg), 2021
RCTsarilumabplaceboCOVID-19 severe or criticallysome concern
173/86 inconclusive
Lescure (Sarilumab 400mg), 2021
RCTsarilumab high dose (400mg)placeboCOVID-19 severe or criticallysome concern
173/86 inconclusive -3%
REMAP-CAP sarilumab, 2021
RCTsarilumabstandard of careCOVID-19 severe or criticallysome concern
48/402 conclusif -44% demonstrated68%
ARI-RAF (Della-Torre), 2020 OBSsarilumabcontrolCOVID-19 severe or criticallyNA
28/28 inconclusive -58%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).